We are live on ! Find out more

Altimmune

ALT

Market cap $605M

3.11 USD

-0.13

4.01%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

3.12

+0.01

0.32%

1 day

-4.01%

5 days

-0.64%

1 month

4.01%

3 months

1.3%

6 months

-25.24%

Year to date

-11.4%

1 year

-16.17%

5 years

-77.93%

10 years

-99.6%

About: Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Employees: 57

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.8%

Neutral 56.5%

Negative 8.7%

Zacks Investment Research

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

Zacks Investment Research

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?

Zacks Investment Research

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune Q2 Earnings Call Highlights

Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.

Altimmune Q2 Earnings Call Highlights

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Global registrational study designed to evaluate pemvidutide on fibrosis improvement, MASH resolution, and clinical outcomes

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript

Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder Transcript

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

Altimmune Inc. (NASDAQ:ALT) has reported positive topline outcomes from its RECLAIM Phase 2 trial assessing pemvidutide in patients diagnosed with moderate to severe alcohol use disorder (AUD).

Altimmune Says Lead Drug Shows Significant Alcohol Reduction in Mid-Stage Study

See News Rankings

Price charts implemented using Lightweight Charts™